Reovirus therapy of tumors with activated Ras pathway

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Human reovirus infection depends on an activated Ras signaling pathway.
• Ras signaling is frequently dysregulated in various human cancers.
• This dependency suggests reovirus as a potential oncolytic agent.

Purpose of the Study:

• To investigate the therapeutic potential of human reovirus against tumors with activated Ras signaling.
• To evaluate reovirus efficacy in preclinical cancer models.

Main Methods:

• Utilized severe combined immune deficient (SCID) mice and immune-competent C3H mice bearing tumors.
• Tumors were established from v-erbB-transformed NIH 3T3 cells, human U87 glioblastoma cells, and ras-transformed C3H-10T1/2 cells.
• Administered human reovirus via intratumoral injection.

Main Results:

• A single intratumoral injection of reovirus achieved 65-80% tumor regression in SCID mice.
• Treatment of tumors in immune-competent mice also resulted in regression, though multiple injections were necessary.
• Demonstrated reovirus's efficacy against different types of Ras-activated tumors.

Conclusions:

• Human reovirus demonstrates significant oncolytic activity against Ras-activated tumors in preclinical models.
• Reovirus warrants further investigation as a potential cancer therapeutic agent.
• The findings support the development of reovirus-based cancer therapies.